Vimarsana
Biggest News Aggregation in the World

Page 2 - Track Designations News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Track Designations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Track Designations Today - Breaking & Trending Today

Genprex Shares Jump 14% Pre-Market on FDA Fast Track Designation - Vimarsana News

Genprex Shares Jump 14% Pre-Market on FDA Fast Track Designation

By Ben Glickman Shares of Genprex were higher early Wednesday after the company said it had received Fast Track Designation from the U.S. Food and Drug...

HUTCHMED Receives Complete Response Letter from the U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors - Vimarsana News

HUTCHMED Receives Complete Response Letter from the U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) announced that the U.S. Food and Drug Administration (“FDA” or the “Agency”) has issued a Complete Response Letter (“CRL”) regarding the New Drug Application (“NDA”) for surufatinib for the treatment of pancreatic (“pNETs”) and ...

HUTCHMED Receives Complete Response Letter from the U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors - Vimarsana News

HUTCHMED Receives Complete Response Letter from the U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
HUTCHMED's Marketing Authorization Application for Surufatinib Submitted and Validated by the European Medicines Agency - Vimarsana News

HUTCHMED's Marketing Authorization Application for Surufatinib Submitted and Validated by the European Medicines Agency

Share: – EMA commences review of surufatinib for the treatment of advanced neuroendocrine tumors – – Expands potential global reach of surufatinib, in addition to China where it is already launched, and in the U.S. where it is under review for marketing approval – HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., July 15, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces that the European Medicines Agency ("EMA") has validated and accepted its marketing authorization application ("MAA") for surufatinib for the treatment of ...